Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Aethlon Medical Inc AEMD

Aethlon Medical, Inc. (Aethlon) is a medical therapeutic company focused on developing the Hemopurifier, a clinical-stage immunotherapeutic device which is designed to combat cancer and life-threatening viral infections suppression, seed the spread of metastasis and inhibit the benefit of cancer therapies. The Hemopurifier is designed to deplete the presence of circulating tumor-derived exosomes that promote immune suppression. Hemopurifier helps to bind and clear multiple different glycosylated viruses, such as human immunodeficiency virus (HIV), hepatitis C virus (HCV), Dengue, West Nile, multiple strains of influenza, Ebola, Chikungunya, smallpox, monkeypox, multiple herpes viruses, a MERS-CoV related pseudovirus, and others. Hemopurifier is used as a device for two independent indications: the treatment of individuals with advanced or metastatic cancer and the treatment of life threating viruses that are not approved therapies.


NDAQ:AEMD - Post by User

Comment by mercedesmanon May 07, 2021 4:16pm
168 Views
Post# 33154646

RE:RE:Reloaded

RE:RE:ReloadedHi Cam

Sorry, I don't come over here often.

Hemopurification is an up and coming science. Recently featured on 60 minutes.  Involves removing various mediators from the blood.  It's been studied for more than 20 years but is getting closer to becoming a reality.

The first one that may make a breakthrough with a Phase 3 Trial is Spectral (EDT). Interim Trial results  expected later this year.   They remove endotoxins that, if elevated can lead to Sepsis (somethign that kills 11m people worldwide annually)

SIGY and CTSO play in this space as well , but ar enot as far along.

Athelon uses hemopurification to remove viruses from the blood.

The Hemopurifier also holds a Breakthrough Device designation related to life-threatening viruses that are not addressed with approved therapies. In June 2020 , the FDA approved an amendment to the Company's existing open IDE for the Hemopurifier in life threatening viral infections, to allow for the treatment of patients with SARS-CoV-2/COVID-19 infection. This will allow for up to 40 of these patients to be treated under a new Early Feasibility Study protocol at up to 20 clinical sites in the U.S.


They are well capitalized having raised money after some spikes in the past few years. 

I am simply trading the (so far inevitable) spikes until they hit on something (the spikes have been berry berry good to me)   Some of the "somethings" that could "hit" include:

- a positive IDE study (Covid)
- another deadly virus emerges (e.g they had some past success against Ebola)
- the FDA approval of another Co's blood filter (hemopurifier).  Best example and arguably the furthest along is SPectral Medical EDT on Toronto.  I own a much bigger position there.  They also have a Covid play as Covid ICU patients often end up with Sepsis/Endotoxemia. If Spectral hits, then likely others (like AEMD) will advance (on proof that blood can be filtered to save lives).

60 minutes featured blood filtration as the latest up and coming science (for cancers, viruses, endotoxins, cytokines, etc.)

Consider it a lottery ticket, without a lot of tickets sold (so far) and very few players.

Ding.  We have arrived at your floor (and hopefully the stock's floor).  Going up?

MM

<< Previous
Bullboard Posts
Next >>